DURHAM, N.C., December 06, 2024 (GLOBE NEWSWIRE) — Chimerix (NASDAQ: CMRX), today announced that on December 2, 2024, the Compensation Committee of the Chimerix Board of Directors awarded bonuses of incentive for three new employees from non-statutory sectors. stock options to purchase up to a total of 385,000 common shares of Chimerix. The Compensation Committee of the Chimerix Board of Directors approved the awards as an employment incentive for new hires, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price per share equal to the closing price of Chimerix on the grant date. The stock options have a term of 10 years and will vest over four years, with one quarter vesting on the first anniversary of the hire date and the remaining three quarters vesting over the following three years in monthly installments equal. The stock options are subject to the terms of the Chimerix 2024 Stock Incentive Plan, but were granted outside of the 2024 Stock Incentive Plan.

Chimerix is ​​a biopharmaceutical company whose mission is to develop medicines that significantly improve and extend the lives of patients facing life-threatening diseases. The Company’s most advanced clinical development program, dordaviprone (ONC201), is under development for H3 K27M mutant glioma. The Company is conducting phase 1 dose-escalation studies of ONC206 to evaluate safety and pharmacokinetic data.

CONTACTS:

Will O’Connor
Severe investor relations
212-362-1200
[email protected]
[email protected]